Resolian developed a hybrid immunocapture nano-LC-MS/MS assay to quantify STAT6, a translational biomarker for RNA-degrading therapeutics, across human tissue types.
Resolian developed and validated a simple, high-throughput HPLC-MS/MS method for simultaneous quantitation of acalabrutinib and its active metabolite ACP-5862 in human plasma, achieving an LLOQ of 1.00 ng/mL with a 20-minute extraction and no carryover.
Resolian developed the first hybrid LC-MS/MS method to achieve 50 pg/mL sensitivity for a duplex siRNA and its N-1 metabolite in human plasma, setting a new benchmark for regulated siRNA bioanalysis.
Resolian developed an extraction-free, direct-to-qPCR workflow that accurately quantifies therapeutic oligonucleotides across plasma and multiple tissue types using a single calibration curve, reducing hands-on time and cost without compromising performance.
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
See how Resolian pairs light microscopy and SEM to reveal structure from macro view to nanoscale, and what this means for your next investigation.
Resolian’s Analytical Sciences team developed a simplified, USP-aligned system suitability test mixture for non-targeted LC-HRAMS extractables and leachables screening, reducing component count from fifteen to fewer than ten while maintaining coverage of all key USP stimulus attributes.
Resolian developed and validated an MSD-based bridging ECLIA method for analysing anti-drug antibodies against a GalNAc-conjugated siRNA therapeutic, evaluating both MSD and Gyrolab platforms for different GalNAc-conjugated siRNA therapeutics and providing a practical framework for immunogenicity assay development in this novel modality.
Resolian developed high-precision LC-MS/MS methods and optimised equilibrium dialysis workflows for plasma protein binding assessment of highly protein-bound compounds, Supporting ICH M12 regulatory expectations across five species.
Resolian developed and validated (following ICH-M10) a high-throughput and robust LC MS/MS method for quantifying intact carboplatin in human plasma, overcoming long-standing challenges around isotopic interference, protein binding, and chromatographic retention.
Chief Scientific Officer
Zhiyang Zhao, Ph.D., serves as Chief Scientific Officer (CSO) at Resolian. Dr. Zhao has over 30 years of pharmaceutical industry experience with special focus on drug metabolism and bioanalysis of small and large molecules in drug discovery and development. Dr. Zhao has previously held positions at Pfizer, GlaxoSmithKline, and Amgen. Before joining Resolian in 2015, Dr. Zhao served as Site Director of Preclinical Research at Amgen in Cambridge, Massachusetts, for over a decade.
Currently, Dr. Zhao serves as an Adjunct Professor at the Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill, North Carolina, and as Editor-in-Chief of Drug Metabolism & Bioanalysis Letters, a journal by Bentham Science, which publishes in all areas of drug metabolism and bioanalysis. Dr. Zhao received his Ph.D. degree in Medicinal Chemistry from Virginia Polytechnic and State University (popularly known as Virginia Tech) in Blacksburg, Virginia.
Chief Executive Officer
Patrick Bennett has over 35 years of experience in pharmaceutical analysis and laboratory management. Now Chief Business Officer at Resolian, Patrick’s experience includes the roles of Strategic Marketing Director for Pharma with Thermo Fisher Scientific, LabCorp, and Vice President of Strategy and Development with PPD.
Patrick earned a B.S. degree in Toxicology and a M.S. degree in Pharmacology from the College of Pharmacy and Allied Health at St. John’s University and an M.B.A in International Marketing from the Martin J. Whitman School of Management at Syracuse University.